ECONSALUT

  Introduction to Market Access for Pharmaceuticals Contents: Chapter 1: Health as a Good Chapter 2: Decision-Making in Public Health Chapte...

 Build a think tank. A guide for policy entrepreneurs Using this guide 8 The reasons for creating this companion guide 8 Using this companio...

 Gene and Cell Therapies-Market Access and Funding Contents: Chapter 1        Introduction to cell and gene therapies concepts and definitio...

 Managed Entry Agreements and Funding for Expensive Therapies Key reference to understand what's going on in this topic. Recommended. Co...

Global Trends in R&D . Overview through 2021  The productivity of the clinical development process can be considered as a measure of tri...

 Building a High- Value Health System Countries and institutions worldwide face the challenge of planning and paying for health care that ef...

Sick Money. The Truth About the Global Pharmaceutical Industry 

 Pharmaceutical innovation sourcing Figure below shows that 23% of new medicines came from public bodies and private-private collaboration a...

Global Trends in R&D. OVERVIEW THROUGH 2021 A decade ago I posted this: Gestionar el declivi . John Kay said in 2011 : "When an ind...

 Today my suggestion is to read the post by Eric Topol with the same title.   It begins with this statement: We’re now well over 20 years si...

 REASONABLE RATIONING. International Experience of Priority Setting in Health Care

Unprecedented. The Rapid Innovation Response to COVID-19 and the Role of Intellectual Property 

 The Political Determinants of Health In this book, Daniel E. Dawes argues that political determinants of health create the social drivers—i...

  Rethinking value in health innovation: from mystifications towards prescriptions From the abstract: Debates over value in health innovatio...